Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors

Chem Pharm Bull (Tokyo). 2022;70(9):637-641. doi: 10.1248/cpb.c22-00303.

Abstract

Human epidermal growth factor (EGFR) is an important target for antitumor drug research. A series of novel quinazolinone derivatives were synthesized and developed as potent inhibitors of EGFR. The results showed that most of the aimed compounds had potential anti-tumor cell proliferation activities. Some compounds were tested for their EGFR inhibitory activity. Especially, compound 6d showed the most potent antitumor activity with IC50 values of 1.58 µM against human breast cancer (MCF-7) cell lines and exhibited the most potent EGFR inhibitory activity with IC50 of 0.77 µM. Docking simulation was performed to position compound 6d into the EGFR active site to determine the probable binding conformation.

Keywords: anti-tumor cell proliferation; epidermal growth factor receptor (EGFR) inhibitory; molecular docking; quinazolinone derivative.

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Design
  • Drug Screening Assays, Antitumor
  • ErbB Receptors
  • Humans
  • Molecular Docking Simulation
  • Molecular Structure
  • Protein Kinase Inhibitors / chemistry
  • Quinazolinones* / chemistry
  • Quinazolinones* / pharmacology
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolinones
  • EGFR protein, human
  • ErbB Receptors